|
1
|
Lewis TS, Shapiro PS and Ahn NG: Signal
transduction through MAP kinase cascades. Adv Cancer Res.
74:49–139. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klapper LN, Kirschbaum MH, Sela M and
Yarden Y: Biochemical and clinical implications of the ErbB/HER
signaling network of growth factor receptors. Adv Cancer Res.
77:25–79. 2000. View Article : Google Scholar
|
|
3
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Downward J, Parker P and Waterfield MD:
Autophosphorylation sites on the epidermal growth factor receptor.
Nature. 311:483–485. 1984. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hurvitz S and Mead M: Triple-negative
breast cancer: advancements in characterization and treatment
approach. Curr Opin Obstet Gynecol. 28:59–69. 2016.
|
|
8
|
DiGiovanna MP, Stern DF, Edgerton SM,
Whalen SG, Moore D II and Thor AD: Relationship of epidermal growth
factor receptor expression to ErbB-2 signaling activity and
prognosis in breast cancer patients. J Clin Oncol. 23:1152–1160.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhargava R, Gerald WL, Li AR, Pan Q, Lal
P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer:
Correlation with epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activating
mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rimawi MF, Shetty PB, Weiss HL, Schiff R,
Osborne CK, Chamness GC and Elledge RM: Epidermal growth factor
receptor expression in breast cancer association with biologic
phenotype and clinical outcomes. Cancer. 116:1234–1242. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burness ML, Grushko TA and Olopade OI:
Epidermal growth factor receptor in triple-negative and basal-like
breast cancer: Promising clinical target or only a marker? Cancer
J. 16:23–32. 2010. View Article : Google Scholar
|
|
12
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sunada H, Magun BE, Mendelsohn J and
MacLeod CL: Monoclonal antibody against epidermal growth factor
receptor is internalized without stimulating receptor
phosphorylation. Proc Natl Acad Sci USA. 83:3825–3829. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vincenzi B, Zoccoli A, Pantano F, Venditti
O and Galluzzo S: Cetuximab: From bench to bedside. Curr Cancer
Drug Targets. 10:80–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawamoto T, Sato JD, Le A, Polikoff J,
Sato GH and Mendelsohn J: Growth stimulation of A431 cells by
epidermal growth factor: Identification of high-affinity receptors
for epidermal growth factor by an anti-receptor monoclonal
antibody. Proc Natl Acad Sci USA. 80:1337–1341. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sforza V, Martinelli E, Ciardiello F,
Gambardella V, Napolitano S, Martini G, Della Corte C, Cardone C,
Ferrara ML, Reginelli A, et al: Mechanisms of resistance to
anti-epidermal growth factor receptor inhibitors in metastatic
colorectal cancer. World J Gastroenterol. 22:6345–6361. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hollestelle A, Elstrodt F, Nagel JHA,
Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or
RAS pathway mutations in human breast cancer cell lines. Mol Cancer
Res. 5:195–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS,
You JF, Hung HY, Tsai CN, Hsu A, Chen HC, et al: Mutations of
KRAS/NRAS/BRAF predict cetuximab resistance in metastatic
colorectal cancer patients. Oncotarget. 7:22257–22270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Macdonald-Obermann JL and Pike LJ:
Different epidermal growth factor (EGF) receptor ligands show
distinct kinetics and biased or partial agonism for homodimer and
heterodimer formation. J Biol Chem. 289:26178–26188. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prat M, Oltolina F and Basilico C:
Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand:
Multitask Tools with Applications from Basic Research to Therapy.
Biomedicines. 2:359–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deb TB, Zuo AH, Barndt RJ, Sengupta S,
Jankovic R and Johnson MD: Pnck overexpression in HER-2
gene-amplified breast cancer causes Trastuzumab resistance through
a paradoxical PTEN-mediated process. Breast Cancer Res Treat.
150:347–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Riese DJ II: Ligand-based receptor
tyrosine kinase partial agonists: New paradigm for cancer drug
discovery? Expert Opin Drug Discov. 6:185–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scott GK, Dodson JM, Montgomery PA,
Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM and Benz CC:
p185HER2 signal transduction in breast cancer cells. J Biol Chem.
266:14300–14305. 1991.PubMed/NCBI
|
|
28
|
Nagata Y, Lan K-H, Zhou X, Tan M, Esteva
FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Esteva FJ, Yu D, Hung M-C and Hortobagyi
GN: Molecular predictors of response to trastuzumab and lapatinib
in breast cancer. Nat Rev Clin Oncol. 7:98–107. 2010. View Article : Google Scholar
|
|
30
|
Yoshida T, Okamoto I, Okabe T, Iwasa T,
Satoh T, Nishio K, Fukuoka M and Nakagawa K: Matuzumab and
cetuximab activate the epidermal growth factor receptor but fail to
trigger downstream signaling by Akt or Erk. Int J Cancer.
122:1530–1538. 2008. View Article : Google Scholar
|
|
31
|
Raben D, Helfrich B, Chan DC, Ciardiello
F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK and Bunn PA Jr:
The effects of cetuximab alone and in combination with radiation
and/or chemotherapy in lung cancer. Clin Cancer Res. 11:795–805.
2005.PubMed/NCBI
|
|
32
|
Molli PR, Adam L and Kumar R: Therapeutic
IMC-C225 antibody inhibits breast cancer cell invasiveness via
Vav2-dependent activation of RhoA GTPase. Clin Cancer Res.
14:6161–6170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
El Guerrab A, Bamdad M, Bignon YJ,
Penault-Llorca F and Aubel C: Anti-EGFR monoclonal antibodies
enhance sensitivity to DNA-damaging agents in BRCA1-mutated and
PTEN-wild-type triple-negative breast cancer cells. Mol Carcinog.
56:1383–1394. 2017. View Article : Google Scholar
|
|
34
|
Hallak H, Moehren G, Tang J, Kaou M, Addas
M, Hoek JB and Rubin R: Epidermal growth factor-induced activation
of the insulin-like growth factor I receptor in rat hepatocytes.
Hepatology. 36:1509–1518. 2002.PubMed/NCBI
|
|
35
|
Saryeddine L, Zibara K, Kassem N, Badran B
and El-Zein N: EGF-Induced VEGF Exerts a PI3K-Dependent Positive
Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro
Models. PLoS One. 11:e01658762016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tuglu MM, Bostanabad SY, Ozyon G, Dalkiliç
B and Gurdal H: The role of dual specificity phosphatase 1 and
protein phosphatase 1 in β2 adrenergic receptor mediated
inhibition of extracellular signal regulated kinase 1/2 in triple
negative breast cancer cell lines. Mol Med Rep. 17:2033–2043.
2018.
|
|
37
|
Solly K, Wang X, Xu X, Strulovici B and
Zheng W: Application of real-time cell electronic sensing (RT-CES)
technology to cell-based assays. Assay Drug Dev Technol. 2:363–372.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Atienza JM, Yu N, Wang X, Xu X and Abassi
Y: Label-free and real-time cell-based kinase assay for screening
selective and potent receptor tyrosine kinase inhibitors using
microelectronic sensor array. J Biomol Screen. 11:634–643. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dynamic Monitoring of Receptor Tyrosine
Kinase Activation in Living Cells Dynamic Monitoring of Receptor
Tyrosine Kinase Activation in Living Cells. ACEA Biosciences, Inc.;
San Diego, CA: 2013
|
|
40
|
Chinkers M, McKanna JA and Cohen S: Rapid
induction of morphological changes in human carcinoma cells A-431
by epidermal growth factors. J Cell Biol. 83:260–265. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bartholomeusz C, Gonzalez-Angulo AM, Liu
P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobágyi GN: High ERK
protein expression levels correlate with shorter survival in
triple-negative breast cancer patients. Oncologist. 17:766–774.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stemke-hale K, Gonzalez-Angulo AM, Lluch
A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et
al: An integrative genomic and proteomic analysis of PIK3CA, PTEN,
and AKT mutations in breast cancer. Cancer Res. 68:6084–6092. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Petreaca ML, Yao M, Liu Y, Defea K and
Martins-Green M: Transactivation of vascular endothelial growth
factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for
IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell.
18:5014–5023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vieira AV, Lamaze C and Schmid SL: Control
of EGF receptor signaling by clathrin-mediated endocytosis.
Science. 274:2086–2089. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carpentier JL: Insulin receptor
internalization: Molecular mechanisms and physiopathological
implications. Diabetologia. 37(Suppl 2): S117–S124. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bruns AF, Herbert SP, Odell AF, Jopling
HM, Hooper NM, Zachary IC, Walker JH and Ponnambalam S:
Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated
trafficking and proteolysis. Traffic. 11:161–174. 2010. View Article : Google Scholar
|
|
47
|
Chow JC, Condorelli G and Smith RJ:
Insulin-like growth factor-I receptor internalization regulates
signaling via the Shc/mitogen-activated protein kinase pathway, but
not the insulin receptor substrate-1 pathway. J Biol Chem.
273:4672–4680. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ferraro DA, Gaborit N, Maron R,
Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit
N, Sela M, et al: Inhibition of triple-negative breast cancer
models by combinations of antibodies to EGFR. Proc Natl Acad Sci
USA. 110:1815–1820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
El Guerrab A, Bamdad M, Kwiatkowski F,
Bignon YJ, Penault-Llorca F and Aubel C: Anti-EGFR monoclonal
antibodies and EGFR tyrosine kinase inhibitors as combination
therapy for triple-negative breast cancer. Oncotarget.
7:73618–73637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sohn J, Liu S, Parinyanitikul N, Lee J,
Hortobagyi GN, Mills GB, Ueno NT and Gonzalez-Angulo AM: cMET
activation and EGFR-directed therapy resistance in triple-negative
breast cancer. J Cancer. 5:745–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li X, Xu L, Li H, Zhao L, Luo Y, Zhu Z,
Liu Y and Qu X: Cetuximab-induced insulin-like growth factor
receptor I activation mediates cetuximab resistance in gastric
cancer cells. Mol Med Rep. 11:4547–4554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rebucci M, Peixoto P, Dewitte A, Wattez N,
De Nuncques MA, Rezvoy N, Vautravers-Dewas C, Buisine MP, Guerin E,
Peyrat JP, et al: Mechanisms underlying resistance to cetuximab in
the HNSCC cell line: Role of AKT inhibition in bypassing this
resistance. Int J Oncol. 38:189–200. 2011.
|
|
53
|
Troiani T, Napolitano S, Vitagliano D,
Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello
F and Martinelli E: Primary and acquired resistance of colorectal
cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway
activation and can be overcome by combined MEK/EGFR inhibition.
Clin Cancer Res. 20:3775–3786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bianco R, Rosa R, Damiano V, Daniele G,
Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R,
et al: Vascular endothelial growth factor receptor-1 contributes to
resistance to anti-epidermal growth factor receptor drugs in human
cancer cells. Clin Cancer Res. 14:5069–5080. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Leto SM and Trusolino L: Primary and
acquired resistance to EGFR-targeted therapies in colorectal
cancer: Impact on future treatment strategies. J Mol Med (Berl).
92:709–722. 2014. View Article : Google Scholar
|
|
56
|
Wheeler DL, Huang S, Kruser TJ,
Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and
Harari PM: Mechanisms of acquired resistance to cetuximab: Role of
HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Iida M, Brand TM, Campbell DA, Starr MM,
Luthar N, Traynor AM and Wheeler DL: Targeting AKT with the
allosteric AKT inhibitor MK-2206 in non-small cell lung cancer
cells with acquired resistance to cetuximab. Cancer Biol Ther.
14:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kim SM, Kim JS, Kim JH, Yun CO, Kim EM,
Kim HK, Solca F, Choi SY and Cho BC: Acquired resistance to
cetuximab is mediated by increased PTEN instability and leads
cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett.
296:150–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
